Investation into risk of heart attack or stroke for patients using Celebrex, which is manufactured by Pfizer Inc. Pfizer has said it has found an increased risk of heart problems including heart attacks with patients taking Celebrex. This warning comes just a few months after Merck removed Vioxx, Celebrex's main competitor, from the market because of cardiovascular side effects. A government-sponsored cancer-prevention trial of Celebrex was halted after patients taking it had more than twice as many heart attacks as patients taking a placebo. The trial was conducted by the National Cancer Institute for Pfizer. The NCI suspended use of the drug after finding that patients taking 400 mg to 800 mg of Celebrex daily had a 2.5 times greater risk of major heart problems than those who were not.
Do not change medications without first consulting your doctor.